Clinical Trials Logo

Unverricht-Lundborg Syndrome clinical trials

View clinical trials related to Unverricht-Lundborg Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT03351569 Active, not recruiting - Clinical trials for Unverricht-Lundborg Disease

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

Start date: December 9, 2015
Phase: Phase 3
Study type: Interventional

Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.

NCT ID: NCT00639119 Enrolling by invitation - Clinical trials for Unverricht-Lundborg Syndrome

Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The progressive myoclonus epilepsy of the Unverricht-Lundborg disease (ULD) type is an autosomal recessive disease characterized by progressive stimulus-sensitive and action-related myoclonic jerks. The mainstay of the current treatment in myoclonic epilepsies including ULD are valproic acid and clonazepam among several other antiepileptic drugs. Unfortunately the disease may often be resistant to antiepileptic drugs leading to major reductions in daily activities and disability to walk without assistance. Therefore new treatment modalities are needed. Experimental treatments of ULD patients with dopamine agonists have relieved myoclonic symptoms. Further, in accordance with this, a recent study indicates decreased dopaminergic neurotransmission in the basal ganglia of ULD patients, determined by PET. The purpose of this study is to investigate the effect of dopaminergic medication (ropinirole hydrochloride, Requip ®) on relieving the symptoms of ULD patients. Patients will undergo sixteen weeks intervention period. The main efficacy determinants are changes in unified myoclonus rating scale (UMRS), nerve conduction, multi-modality evoked potentials including visual evoked potential (VEP), somatosensory evoked potential (SSEP) and brainstem auditory evoked potential (BAEP), blink reflex habituation and electroencephalography (EEG). Tolerability and the safety of the medication are determined. The study setting is placebo controlled, crossover, two-group and double blind study.

NCT ID: NCT00368251 Completed - Clinical trials for Unverricht-Lundborg Disease

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).

NCT ID: NCT00357669 Completed - Clinical trials for Unverricht-Lundborg Disease

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.